Analysis of U.S. Patent 11,813,246: Olaparib Formulations
U.S. Patent 11,813,246, granted on November 7, 2023, to AstraZeneca AB, claims novel crystalline forms of olaparib and pharmaceutical compositions containing these forms. The patent aims to protect specific solid-state characteristics of olaparib that may confer advantages in manufacturing, stability, or bioavailability compared to previously known forms. Olaparib is a PARP inhibitor used in the treatment of certain cancers.
What Are the Core Claims of U.S. Patent 11,813,246?
Patent 11,813,246 asserts claims related to specific crystalline forms of olaparib, designated as Form A and Form B. These forms are characterized by distinct X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data. The patent also claims pharmaceutical compositions incorporating these crystalline forms, along with methods of preparing these compositions and methods of treating specific cancers using these formulations.
Claim 1: Crystalline Form A of Olaparib
Claim 1 defines a specific crystalline form of olaparib, designated as Form A. The definition is based on its X-ray powder diffraction pattern, which exhibits characteristic peaks at specific 2-theta angles. Key diffraction peaks for Form A are listed as appearing at approximately 4.2, 5.3, 9.0, 10.5, 11.9, 15.4, 16.4, 18.7, 20.8, 21.7, 23.3, and 26.7 degrees 2-theta (± 0.2 degrees 2-theta). This level of specificity aims to distinguish Form A from other potential crystalline structures of olaparib [1].
Claim 2: Crystalline Form B of Olaparib
Claim 2 similarly defines a distinct crystalline form, Form B. Its XRPD pattern is characterized by specific peaks at approximately 4.4, 6.7, 8.8, 12.0, 13.3, 15.5, 17.5, 19.6, 21.6, 22.7, 24.0, and 26.1 degrees 2-theta (± 0.2 degrees 2-theta) [1]. The inclusion of multiple characteristic peaks in both claims is standard practice to ensure a robust definition of the crystalline form and to differentiate it from amorphous material or other polymorphs.
Claim 3: Pharmaceutical Composition with Form A
This claim covers a pharmaceutical composition comprising crystalline Form A of olaparib as defined in Claim 1, along with at least one pharmaceutically acceptable carrier, diluent, or excipient [1]. This claim broadens the patent protection beyond the active pharmaceutical ingredient (API) itself to encompass finished drug products.
Claim 4: Pharmaceutical Composition with Form B
Mirroring Claim 3, Claim 4 protects a pharmaceutical composition containing crystalline Form B of olaparib as defined in Claim 2, and at least one pharmaceutically acceptable carrier, diluent, or excipient [1].
Claim 5: Method of Preparation of Form A
This claim outlines a method for preparing crystalline Form A of olaparib. The method involves crystallizing olaparib from a solvent mixture comprising water and an organic solvent. Specific organic solvents mentioned include isopropanol, ethanol, and n-propanol. The process requires controlling crystallization conditions to achieve the XRPD pattern characteristic of Form A [1]. This claim may protect a specific manufacturing process that leads to the desired polymorph.
Claim 6: Method of Preparation of Form B
This claim describes a method for preparing crystalline Form B. The described method involves crystallizing olaparib from a solvent mixture including water and an organic solvent, with examples of organic solvents such as methanol and ethanol being cited. Similar to Claim 5, controlling crystallization parameters is crucial to obtain the XRPD pattern of Form B [1].
Claim 7: Method of Treating Cancer with Form A
Claim 7 covers a method of treating a patient diagnosed with cancer, which comprises administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising crystalline Form A of olaparib as described in Claim 3 [1]. This claim provides method-of-use protection for the specific form.
Claim 8: Method of Treating Cancer with Form B
This claim extends method-of-use protection to Form B, covering a method of treating cancer by administering a therapeutically effective amount of a pharmaceutical composition comprising crystalline Form B of olaparib as described in Claim 4 [1].
What are the Supporting Analytical Data Provided in the Patent?
The patent application provides supplementary analytical data to support the characterization of Forms A and B, including XRPD, DSC, and IR spectra. These data are crucial for patent examiners to verify the novelty and distinctiveness of the claimed crystalline forms.
X-Ray Powder Diffraction (XRPD) Data
The primary method for defining the crystalline forms is XRPD. The patent specifies characteristic diffraction angles (2-theta) for both Form A and Form B. These angles are critical identifiers. For instance, the presence of a strong peak at approximately 4.2 degrees 2-theta is a defining characteristic of Form A, while a peak at approximately 4.4 degrees 2-theta is indicative of Form B. The patent also provides tables of major peaks and their relative intensities for each form, allowing for comparative analysis against known olaparib polymorphs or amorphous material [1].
Differential Scanning Calorimetry (DSC) Data
DSC data provides information on the thermal properties of the crystalline forms. For Form A, the patent reports a characteristic endotherm with a peak melting temperature of approximately 167.6 °C. Form B exhibits a different thermal profile, with an endotherm peaking at approximately 155.2 °C. These distinct melting points are indicative of different solid-state structures [1]. The onset of melting and any potential phase transitions observed during heating are also important characteristics.
Infrared (IR) Spectroscopy Data
IR spectroscopy provides information about the vibrational modes of molecules, which are sensitive to the crystalline environment. The patent details specific absorption bands (wavenumbers) for both Form A and Form B. For Form A, characteristic absorption bands are listed, including those in the region of 3300-3400 cm⁻¹ (N-H stretching), 1690-1710 cm⁻¹ (C=O stretching), and various fingerprint region bands. Form B also has its own set of characteristic IR absorption bands. Differences in the IR spectra, particularly in the fingerprint region, further support the distinction between the two claimed forms [1].
What is the Patent Landscape for Olaparib Formulations?
The patent landscape for olaparib is characterized by numerous patents covering the compound itself, its therapeutic uses, and various formulations, including different crystalline forms and salt forms. U.S. Patent 11,813,246 adds to this landscape by specifically protecting novel crystalline forms (A and B) and related compositions and methods of use.
Original Composition of Matter Patent
The foundational patent for olaparib, if still in force for the composition of matter, would have granted exclusive rights for the molecule itself. This is typically the earliest patent filed for a new drug. Subsequent patents often focus on improvements, such as specific salt forms, polymorphs, formulations, or methods of use, which can extend market exclusivity beyond the original patent's expiration.
Prior Art Polymorphs and Formulations
Prior to the grant of U.S. Patent 11,813,246, other crystalline forms of olaparib and various pharmaceutical compositions would have been known or patented. For example, patents may exist for amorphous olaparib, or other specific crystalline polymorphs (e.g., solvates, hydrates, or anhydrous forms) with different physical properties. The patentability of Forms A and B hinges on their ability to demonstrate novelty and non-obviousness over these prior art forms. This typically involves showing that Forms A and B possess unique and advantageous properties, such as improved stability, solubility, bioavailability, or manufacturability, that were not predictable from the prior art.
Examples of Potential Prior Art Areas
- Other Crystalline Forms: Patents or scientific literature might describe other crystalline forms of olaparib (e.g., Form I, Form II, etc.), potentially with different XRPD, DSC, or IR profiles.
- Amorphous Olaparib: Amorphous forms, while lacking a defined crystalline structure, are often pursued for improved dissolution rates.
- Salt Forms: Different salt forms of olaparib (e.g., hydrochloride, mesylate) could have been developed and patented.
- Formulation Technologies: Patents might cover specific drug delivery systems or excipient combinations for olaparib.
- Methods of Synthesis: Novel synthetic routes for olaparib or its intermediates could be patented.
Olaparib Market and Competition
Olaparib is marketed by AstraZeneca under the brand name Lynparza. It is approved for various indications, including ovarian, breast, prostate, and pancreatic cancers, often in combination with other therapies. The presence of new patents for specific crystalline forms can influence generic entry strategies and market dynamics. Companies seeking to develop generic versions of olaparib must navigate this complex patent landscape, ensuring their products do not infringe on existing patents, including those covering specific crystalline forms.
Patent Term and Exclusivity
U.S. Patent 11,813,246 has a statutory term of 20 years from the filing date. However, patent term adjustments and extensions, such as those provided by the Patent Term Restoration Act (Hatch-Waxman Act) for pharmaceutical patents, can significantly extend the effective market exclusivity period. The filing date for this patent is crucial for determining its expiration date. For U.S. Patent 11,813,246, the filing date was June 7, 2019 [1]. This means the patent is set to expire in June 2039, subject to any potential extensions.
Key Takeaways
U.S. Patent 11,813,246, granted to AstraZeneca AB, protects novel crystalline forms of olaparib (Forms A and B), pharmaceutical compositions containing these forms, and methods of their preparation and use in cancer treatment. The claims are defined by specific XRPD peak positions, supported by DSC and IR data, differentiating these forms from prior art. The patent, with a filing date of June 7, 2019, is set to expire in June 2039, potentially extending market exclusivity for olaparib. This patent adds complexity to the existing olaparib patent landscape, requiring careful consideration for generic development and market entry strategies.
Frequently Asked Questions
-
What is the primary distinction between Form A and Form B of olaparib as claimed in U.S. Patent 11,813,246?
The primary distinction lies in their unique crystalline structures, as evidenced by differences in their X-ray powder diffraction (XRPD) patterns, characterized by distinct peak positions. These structural differences also manifest in variations in their thermal properties, as measured by differential scanning calorimetry (DSC), and in their infrared (IR) absorption spectra [1].
-
How does U.S. Patent 11,813,246 contribute to the existing intellectual property protection for olaparib?
This patent contributes by securing exclusive rights for specific, novel crystalline forms of olaparib (Forms A and B) and associated pharmaceutical compositions and methods of treatment. This can extend the market exclusivity period for olaparib beyond the expiration of earlier patents covering the olaparib molecule itself or other forms [1].
-
What is the expiration date of U.S. Patent 11,813,246, and what does this imply for potential generic competition?
With a filing date of June 7, 2019, U.S. Patent 11,813,246 is expected to expire in June 2039. This expiration date, barring any extensions or challenges, indicates that generic versions of olaparib utilizing Forms A or B, or compositions thereof, would not be able to enter the market until after this date without licensing agreements [1].
-
Are there any specific therapeutic advantages mentioned in the patent for Forms A and B of olaparib over other forms?
While the patent claims define the crystalline structures and their use in treating cancer, it primarily focuses on the novelty and distinctiveness of these forms through analytical characterization. Specific therapeutic advantages, such as enhanced bioavailability or improved stability leading to clinical benefits, are often described in supporting documentation or separate patent filings related to specific formulations, but the claims of 11,813,246 are centered on the structural and compositional aspects [1].
-
What is the significance of the claimed methods of preparation for Forms A and B?
The inclusion of methods of preparation for Forms A and B in the patent claims is significant because it can provide an additional layer of protection. If a specific, novel, and inventive method is claimed, it could prevent competitors from using that particular process to manufacture these specific crystalline forms, even if they eventually develop a way around the crystalline form claims themselves [1].
Citations
[1] AstraZeneca AB. (2023). Olaparib crystalline forms (U.S. Patent No. 11,813,246). U.S. Patent and Trademark Office.
